Details for Patent: 8,875,704

Which drugs does patent 8,875,704 protect, and when does it expire?

Patent 8,875,704 protects ONZETRA XSAIL and is included in one NDA.

This patent has three patent family members in two countries.

Summary for Patent: 8,875,704

Title:	Nasal administration
Abstract:	A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
Inventor(s):	Per Gisle Djupesland, Roderick Peter Hafner
Assignee:	Optinose Inc
Application Number:	US14/274,271
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Device; Dosage form;

# United States Drug Patent 8,875,704: Claim Scope, Exclusivity, Litigation Risk and Sumatriptan Nasal-Delivery Patent Landscape

US 8,875,704 protects a breath-powered nasal delivery system for powdered sumatriptan. Its core combination is a rotatable capsule in an airflow passage, a nosepiece connected to that passage, and exhalation-driven bidirectional airflow through the nasal passages. The broadest independent claims also require defined particle-size characteristics. The patent is directed to the device and treatment method rather than to sumatriptan as a chemical compound.

The patent’s principal commercial relevance is the Onzetra Xsail product, an exhalation-powered sumatriptan nasal powder product approved by the FDA in 2016. The nominal patent-term endpoint is June 8, 2027, based on the family’s earliest claimed priority date. A definitive launch analysis requires review of any patent-term adjustment, terminal disclaimer, Orange Book listing and current litigation record. [1-3]

What does US Patent 8,875,704 protect?

US 8,875,704 protects a combination of formulation, capsule geometry, airflow mechanics and treatment use. The claims do not broadly cover every sumatriptan nasal powder or every nasal delivery device.

The independent claims divide into three groups:

Claim group	Independent claim	Principal subject matter
Device with particle-size limitation	1	Nasal device, rotatable capsule, bidirectional exhalation airflow and specified sumatriptan particle-size distribution
Excipients-free device	15	Same platform, limited to sumatriptan succinate containing no introduced excipients or adjuvants
Alternative device wording	17	Nasal device using powdered sumatriptan, with the same airflow, capsule and particle-size architecture

Claims 10 through 14 are method claims. They require use of the claimed device to treat headache, including migraine or cluster headache, and in some claims require sequential use of first and second delivery devices in the two nostrils.

A competing product would generally need to satisfy every limitation of at least one asserted claim for literal infringement. A device that uses a non-rotating capsule, does not create the specified bidirectional flow, uses a different particle-size profile, or contains introduced excipients may avoid some claims while potentially remaining exposed to other family patents.

How broad are the independent claims?

Claim 1: device, capsule, airflow and particle size

Claim 1 requires all of the following:

1. A nasal delivery device for powdered sumatriptan.
2. A nosepiece fitting the subject’s nasal cavity.
3. A capsule-containing member.
4. A capsule disposed in a flow passage.
5. A capsule configured to rotate when airflow passes through the passage.
6. An inlet and outlet, with the outlet in fluid communication with the nosepiece.
7. Oral exhalation through the device that closes the velum.
8. Airflow through the nasal cavity from one nasal passage and out the other.
9. A particle-size distribution of:
   • D10 below about 20 micrometers;
   • D50 below about 50 micrometers; and
   • D90 below about 150 micrometers.

This is a combination claim. The particle-size limits alone do not create infringement. A product must also use the claimed capsule-in-passage arrangement and exhalation-driven bidirectional nasal airflow.

The claim language creates several potential claim-construction disputes. “Configured such that” may be argued to require a structural capability rather than proof that every patient produces the claimed airflow. “Rotatable therewithin” may require the capsule to rotate inside the flow passage, rather than merely vibrate or move. “Bi-directional air flow” ties the device to a particular exhalation mechanism in which air enters one nostril and exits the other.

Claim 15: excipient-free sumatriptan succinate

Claim 15 is narrower than claim 1 because it requires the powdered substance to contain only sumatriptan succinate and no introduced excipients or adjuvants. It retains the capsule, airflow, nosepiece and particle-size requirements.

This limitation is commercially significant. A powder formulation containing a carrier, dispersant, lubricant or other intentionally introduced additive could fall outside claim 15. The formulation must be assessed by composition, manufacturing process and finished-product specifications. Naturally occurring or process-derived materials could become relevant to the interpretation of “only,” depending on the evidence and claim construction.

Claim 17: powdered sumatriptan

Claim 17 uses “powdered sumatriptan” rather than the more specific sumatriptan succinate wording in claim 15. Claim 18 expressly identifies sumatriptan base or sumatriptan succinate. Claim 19 then narrows the claim to excipient-free sumatriptan succinate, and claim 20 requires 10 mg of sumatriptan succinate powder.

The practical scope is therefore layered:

Claim	Formulation scope	Dose limitation
1	Sumatriptan base or succinate under claim 6; broader claim 1 text is formulation-neutral	None
15	Only sumatriptan succinate; no introduced excipients or adjuvants	None
16	Same as claim 15	10 mg
17	Powdered sumatriptan	None
18	Sumatriptan base or succinate	None
19	Only sumatriptan succinate; no introduced excipients or adjuvants	None
20	Same as claim 19	10 mg

What formulations are protected by US 8,875,704?

The patent covers powdered sumatriptan formulations that meet the claimed particle-size profile and are delivered through the specified capsule device. The claims expressly encompass sumatriptan base and sumatriptan succinate through dependent claims 6 and 18.

The strongest formulation-specific protection is in claims 15, 16, 19 and 20. These claims focus on an excipient-free sumatriptan succinate powder, including a 10 mg dose.

The particle-size limitations are central:

Particle-size parameter	Primary threshold	Narrower dependent threshold
D10	Less than about 20 µm	Less than about 10 µm
D50	Less than about 50 µm	Less than about 30 µm
D90	Less than about 150 µm	Less than about 90 µm

A product specification using a different distribution may avoid the literal particle-size limitation. The use of “about” creates a zone for dispute based on analytical method, sampling, batch variation and accepted measurement tolerances. Particle-size testing would be a central issue in both patent enforcement and Paragraph IV certification analysis.

The claims do not require a particular crystalline form, polymorph, salt particle morphology, capsule shell composition or manufacturing process. Those subjects may be protected by separate patents or applications in the same family or by unrelated formulation patents.

How does the capsule and airflow mechanism limit infringement?

The claims require a capsule located in a flow passage and capable of rotating when air flows through it. This architecture is more specific than a conventional nasal spray, passive powder inhaler or reservoir-based powder dispenser.

The dependent claims add the following limitations:

• Claim 2 requires an inlet aperture that restricts airflow.
• Claim 3 requires the inlet aperture to provide a seat for the lower end of the capsule before use.
• Claim 4 requires an elongate flow passage with the capsule axially oriented.
• Claim 5 covers a replaceable nosepiece unit.
• Claims 10 through 14 require capsule piercing and exhalation-driven powder entrainment.

A design using a blister, foil pouch, metered reservoir, vibrating capsule or pressure-driven aerosol could avoid these limitations if it does not retain the claimed rotatable capsule and bidirectional airflow architecture. A replaceable cartridge may still present risk if the cartridge incorporates the claimed capsule-containing member and the accused system uses the claimed airflow path.

The method claims create a separate enforcement route. Claims 10 and 11 require fitting a housing and mouthpiece unit, piercing the capsule and using exhalation to rotate the capsule and entrain the powder. Claim 11 adds sequential use of first and second delivery devices, while claims 12 and 13 specify cluster headache and migraine treatment.

When does US 8,875,704 lose exclusivity?

The patent’s nominal expiration date is June 8, 2027, assuming the earliest claimed priority date is June 8, 2007 and no applicable patent-term adjustment changes the endpoint. The patent term is ordinarily measured from the earliest effective nonprovisional or international application date in the priority chain, not from the grant date. [1,2]

Event	Date
Earliest claimed priority	June 8, 2007
US patent grant	November 4, 2014
Nominal 20-year term endpoint	June 8, 2027
FDA approval of Onzetra Xsail	January 2016
Expected patent-term endpoint	June 8, 2027, subject to USPTO term calculations

FDA approval does not itself extend a device or formulation patent. Patent-term extension under 35 U.S.C. §156 and patent-term adjustment under 35 U.S.C. §154 can produce different results, but the applicable USPTO term data must control. [2,4]

US 8,875,704 is not a patent on the sumatriptan molecule. Generic manufacturers can market sumatriptan in other dosage forms after the relevant drug-substance and product exclusivities expire, subject to their own patent and regulatory obligations.

What is the Orange Book status of US 8,875,704?

Onzetra Xsail was approved under NDA 205831 as a sumatriptan nasal powder product using the Xsail exhalation delivery system. The FDA label identifies the product as a single-use nasal delivery system containing 11 mg of sumatriptan succinate, equivalent to 10 mg of sumatriptan. [3]

The Orange Book analysis must distinguish among:

• patents listed against NDA 205831;
• patents in the broader Onzetra or Optinose family;
• patents covering the device;
• patents covering the drug product or method of use;
• patents listed against later or related products.

A device patent is not automatically Orange Book-listable merely because the device is supplied with an approved drug. FDA listing turns on the statutory and regulatory requirements for patents claiming the drug substance, drug product or approved method of use. A patent that covers only a delivery device may have enforcement value without appearing in the Orange Book. [4]

For generic applicants, an Orange Book-listed patent can trigger a Paragraph IV certification and potential litigation under the Hatch-Waxman framework. A non-listed device patent may still support an infringement action, but it generally does not create the same automatic 30-month stay mechanism.

Which companies are challenging the patent estate?

The commercial challenge is likely to arise from three groups:

1. Generic pharmaceutical companies seeking sumatriptan nasal products.
2. Device companies developing capsule-based nasal powder systems.
3. Combination-product companies seeking an alternative exhalation-powered platform.

A standard sumatriptan nasal spray is not necessarily a direct substitute for the claimed product. The strongest design-around candidates would use a different delivery architecture, such as a liquid spray, a non-rotating powder reservoir or a one-way airflow configuration.

No specific Paragraph IV challenger, ANDA number, settlement agreement or litigation disposition should be attributed to US 8,875,704 without a verified FDA Orange Book record, ANDA notice or court docket. The supplied claim set establishes technical scope but does not establish a particular challenger or settlement.

What patent litigation affects US 8,875,704?

The principal litigation risks would concern four technical questions:

Infringement questions

• Whether the accused capsule rotates inside the airflow passage.
• Whether exhalation produces airflow through one nasal passage and out the other.
• Whether the powder meets the D10, D50 and D90 thresholds.
• Whether the product contains introduced excipients or adjuvants.

Validity questions

• Whether prior art disclosed an exhalation-powered bidirectional nasal device.
• Whether a rotatable capsule and restricted inlet aperture were obvious combinations.
• Whether the particle-size profile provides an unexpected technical effect.
• Whether the claims adequately define “about,” “only,” “bi-directional” and “configured such that.”
• Whether the method claims improperly depend on patient physiology or doctor-directed use.

Enablement and written-description questions

The patent must support the claimed range of particle sizes, both sumatriptan base and succinate embodiments, and the stated airflow mechanism. Broader claims 1 and 17 may face greater validity pressure than claims limited to 10 mg excipient-free sumatriptan succinate.

Settlement exposure

A settlement with an ANDA filer could establish an agreed launch date before June 2027, but no settlement terms can be inferred from the claim language. A generic could also launch after a non-infringement or invalidity determination, subject to any separate, unexpired family patents.

How strong is the patent estate for Onzetra Xsail?

US 8,875,704 has meaningful blocking value against a close technical copy of the Xsail platform. Its strength is highest where a competing product reproduces all four core elements:

1. Exhalation-driven bidirectional nasal airflow.
2. A capsule that rotates in the airflow passage.
3. Powdered sumatriptan with the claimed particle-size distribution.
4. A nosepiece and capsule-containing delivery assembly.

Its scope is weaker against:

• liquid sumatriptan nasal sprays;
• conventional nasal powder sprays;
• formulations with materially different particle-size distributions;
• devices using a non-rotating capsule;
• devices using unilateral airflow;
• products containing deliberately introduced excipients where only excipient-free claims are asserted.

The estate should be evaluated as a family rather than by this patent alone. Related patents may cover device architecture, capsule piercing, airflow control, dose preparation, formulations, methods of use or replaceable cartridge construction. A freedom-to-operate opinion limited to US 8,875,704 would not clear the full Onzetra platform.

How does US 8,875,704 compare with competing sumatriptan products?

Product or platform	Dosage form	Exhalation-powered bidirectional airflow	Rotatable capsule	Direct overlap risk
Onzetra Xsail	Sumatriptan nasal powder	Yes	Yes	High
Conventional sumatriptan nasal spray	Liquid spray	No	No	Low under these claims
Oral sumatriptan tablet	Solid oral dosage form	No	No	None under these device claims
Sumatriptan injection	Injectable solution	No	No	None under these device claims
Alternative nasal powder device	Powder	Depends on design	Depends on design	Medium to high
Exhalation-powered non-sumatriptan device	Other active ingredient	Potentially yes	Potentially yes	No literal sumatriptan-product infringement, but platform patents may apply

The patent is therefore a platform-and-product combination patent. It does not block the full triptan market, but it can materially constrain a close copy of the approved powder-delivery configuration.

What generic launch risks exist after patent expiration?

After the relevant patent barriers expire, a generic launch could use an ANDA if the reference product and regulatory pathway remain suitable. The principal regulatory issues would include bioequivalence, dose delivery, nasal deposition, device performance, capsule integrity, particle-size control and human-factors requirements.

A generic could pursue an earlier launch through:

• Paragraph IV certification against listed patents;
• a non-infringing formulation or device design;
• a post-expiration launch;
• a licensed or authorized-generic arrangement;
• a 505(b)(2) strategy if the product differs materially from the reference product.

The highest-risk launch design would replicate the Xsail device, use 10 mg equivalent sumatriptan succinate, meet the claimed particle-size profile and reproduce the bidirectional exhalation pathway. A liquid nasal spray or non-rotating powder system would face a different patent analysis and potentially different FDA requirements.

Key Takeaways

• US 8,875,704 protects a specific exhalation-powered nasal powder system for sumatriptan.
• The core limitations are bidirectional nasal airflow, a rotatable capsule in a flow passage and defined powder particle size.
• Claims 15, 16, 19 and 20 add the commercially important excipient-free sumatriptan succinate limitation.
• Claims 10 through 14 cover treatment methods involving capsule piercing, exhalation and, in some cases, sequential use in both nostrils.
• The nominal patent-term endpoint is June 8, 2027, subject to official USPTO term calculations.
• The patent is not a compound patent on sumatriptan and does not block tablets, injections or unrelated nasal formulations.
• The principal design-around paths are non-rotating capsules, non-bidirectional airflow, different particle-size distributions and formulations with introduced excipients.
• Orange Book listing and Paragraph IV exposure must be confirmed separately from the patent’s technical claim scope.
• The patent should be analyzed with the full Optinose/Onzetra family before making a freedom-to-operate, licensing or generic-launch decision.

FAQs

Is US 8,875,704 a patent on Onzetra Xsail?

It is directed to the technical combination used by the Onzetra Xsail product, including the nasal device, rotatable capsule, exhalation-driven bidirectional airflow and powdered sumatriptan. It is not the only patent that may be relevant to the product.

Does a sumatriptan nasal spray infringe US 8,875,704?

A conventional liquid sumatriptan nasal spray would generally lack the claimed capsule, rotatable capsule mechanism and exhalation-driven bidirectional airflow. It would therefore have a lower literal infringement risk under the supplied claims.

Does the patent cover sumatriptan base?

Claim 6 identifies sumatriptan base or sumatriptan succinate, and claim 18 does the same. Claims directed specifically to excipient-free material require sumatriptan succinate under claims 15, 19 and their dependents.

Can a competitor avoid the patent by changing the powder particle size?

Changing particle size may avoid the particle-size limitations in claims 1, 9 and 17, but it may not avoid other patents covering the device, capsule, formulation or method. The measurement method and the meaning of “about” would also affect the analysis.

Does patent expiration eliminate FDA exclusivity?

No. Patent expiration and FDA regulatory exclusivity are separate. A generic applicant must satisfy applicable FDA requirements, and other unexpired patents or regulatory exclusivities may still affect launch timing.

References

1. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,875,704, Nasal delivery device.
2. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources.
3. U.S. Food and Drug Administration. (2016). Onzetra Xsail prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

Drugs Protected by US Patent 8,875,704

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y			METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Foreign Priority and PCT Information for Patent: 8,875,704

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0706744.0	Apr 5, 2007

International Family Members for US Patent 8,875,704

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
United Kingdom	0706744
United Kingdom	2448183
World Intellectual Property Organization (WIPO)	2008122795